Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Feb 7 2019

Six Miscarriages, a Severe Liver Disease, and a Dream

Oshrat Ohana Nagar was a busy newspaper journalist, a self-proclaimed workaholic, and a mother of two children. Shortly after the birth of her second child, however, she began to experience pain throughout her body.

READ MORE ›
alt_text

Wednesday, Feb 6 2019

Hadassah Hematologist Dina Ben-Yehuda: Healer, Researcher, Mentor, and Dean

During this age of big data and artificial intelligence, Prof. Dina Ben-Yehuda, head of the Hadassah Medical Organization’s Department of Hematology and now also the first female dean of the Hadassah-Hebrew University School of Medicine, believes that the “role of physician as healer is more necessary for patients than ever.”

READ MORE ›
alt_text

Wednesday, Feb 6 2019

Hadassah Eye Specialists Take Their Expertise to Nursing Homes

Saving nursing home residents from the burden of commuting to the hospital for eye examinations, Hadassah Medical Organization ophthalmologists and optometrists have begun bringing their expertise to the seniors’ home setting.

READ MORE ›
alt_text

Monday, Feb 4 2019

Hadassah Breast Imaging Specialist Offers Perspective on Preventive Care

The most important adversary to breast cancer screening is fear, says Dr. Tamar Sella, head of the Marlene Greenebaum Multidisciplinary Diagnostic Breast Center at the Hadassah Medical Organization.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More